<DOC>
	<DOCNO>NCT02214927</DOCNO>
	<brief_summary>- Characterisation relative bioavailability IR-tablet vs. oral drinking solution ( primary endpoint statistical sense ) - Safety tolerability IR-tablet formulation solution - PK profile single ascend dos IR-tablet formulation ( include analysis dose proportionality )</brief_summary>
	<brief_title>Pharmacokinetics Relative Bioavailability 11634 Immediate Release Tablet Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy Caucasian male accord follow criterion , base upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test Age ≥18 ≤50 year Haemoglobin within normal range Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Relevant surgery gastrointestinal tract History bleed disorder acute chronic blood coagulation defect , subject person family far known History gastric ulcera cholecystectomy Occult blood faeces Relevant diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout Relevant chronic acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Use acetylsalicylic acid nonsteroidal antiinflammatory drug ( NSAID ) within 2 week study start end study Participation another trial investigational drug within two month prior administration trial Alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Vulnerable subject ( e.g . person keep detention ) Inability understand comply protocol requirement , instruction protocolstated restriction , nature , scope possible consequence study Subjects ( include vasectomy ) agree use two method contraception , include barrier contraception ( latex condom spermicide plus intrauterine device ) engage sexual activity woman child bear potential study 60 day completion study Subjects history within past six week closedhead torso trauma deceleration injury automobile accident fall significant height</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>